NDA 216264 · Provepharm Sas
Bludigo
Indigotindisulfonate Sodium · Intravenous
Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jul 8, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 1 recruiting
FAERS reports
4
4 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
BLUDIGO is indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. ( 1 )
Mechanism: Indigotindisulfonate is a dye excreted by the kidney through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 8, 2022 Original approval · Type 7 - Drug Already Marketed without Approved NDA LetterLabelReview
1 products under this application
- BLUDIGO · INDIGOTINDISULFONATE SODIUM 40MG/5ML (8MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Indigotindisulfonate" as an intervention, any sponsor and status, largest first.
- Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral PatencyPivotal-lookingCompleted
Prove pharmIndustry
NCT06054880 · 117 participants · Start Oct 12, 2023 · Primary completion Mar 30, 2026
Drug: Indigotindisulfonate sodium 0.8% · For: Ureter Injury
Sites: Albany, New York
Prove pharmIndustry
NCT06085183 · 48 participants (planned) · Start Dec 20, 2023 · Primary completion Dec 30, 2026
Drug: Indigotindisulfonate sodium 0.8% · For: Ureter Injury
Sites: Albany, New York
- Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric PatientsPivotal-lookingNot yet recruiting
Prove pharmIndustry
NCT06448143 · 18 participants (planned) · Start Dec 2026 · Primary completion Dec 2026
Drug: Indigotindisulfonate sodium 0.8% injection · For: Ureter Injury
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT01767415 · 10 participants · Start Apr 2012 · Primary completion Apr 2014
Drug: Indigo carmine · For: Brain Tumors With Ill-defined Margins
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic reaction1
- cheilitis1
- dermatitis1
- drug ineffective1
- extravasation1
- radiation skin injury1
- reaction to excipient1
- stomatitis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2015 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Provepharm Sas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.